Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients

19 May 2022

Abstract excerpt

In summary, we found that baseline ctNDA was highly correlated with disease stages, but it was a poor prognostic marker. In contrast, ctDNA collected 1 month post-CRT/RT was the optimal to predict patients’ PFS and OS, and the dynamic change in ctDNA was closely associated with clinical outcomes. Our results further expanded the clinical utility of ctDNA for the early estimation of prognosis and timely adjustment...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to Cancer Genomics and Diagnostics
Share to Hepatocellular Carcinoma Treatment and Prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35590322
DOI: 10.1186/s12943-022-01590-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patientsPMID 35590322Read ↗

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read ↗

Predicting Disease Progression in Inoperable Localized NSCLC Patients Using ctDNA Machine Learning Model.Semantic proximity Read ↗

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity Read ↗

Integrating clinico-pathological features and longitudinal liquid biopsy results to predict clinical benefit from immune checkpoint Inhibitors in advanced Non-Small Cell Lung Cancer patientsSemantic proximity Read ↗

Clinical Implication of Monitoring Circulating Tumor DNA in Untreated Non-Small-Cell Lung Cancer PatientsSemantic proximity Read ↗

NGS-based Tissue-Blood TMB Comparison and Blood-TMB Monitoring in Stage-III Non-Small Cell Lung Cancer Treated with Concurrent Chemoradiotherapy.Semantic proximity Read ↗

Dynamic Surveillance of Minimal Residual Disease via a Tumor-Informed Circulating Tumor DNA Assay for Outcome Prediction in Small-Cell Lung Cancer: A Prospective Pilot StudySemantic proximity Read ↗

Lung cancer: Using ctDNA to track EGFR and KRAS mutations in advanced-stage disease.Semantic proximity Read ↗

Personalized circulating tumor DNA detection for monitoring immunotherapy efficacy in locally advanced or metastatic non-small cell lung cancerSemantic proximity Read ↗

Dynamic analysis of circulating tumor DNA to predict the prognosis and monitor the treatment response of patients with metastatic triple-negative breast cancer: A prospective study.Semantic proximity Read ↗

ctDNA-adjusted bTMB as a predictive biomarker for patients with NSCLC treated with PD-(L)1 inhibitors.Semantic proximity Read ↗

Quantification of circulating cell-free DNA to predict patient survival in non-small-cell lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.